Drug news
MiStent (Micell Technologies) enters Phase III trial for CAD
Micell Technologies,Inc. announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lesions in the native coronary arteries) clinical trial. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent Drug-Eluting Coronary Stent System and compares the MiCell MiStent with the Medtronic Inc. Endeavour drug eluting stent.